Compare Allegion PLC (ALLE) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Enveric Biosciences Inc — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: Allegion PLC is far larger — about 2158.1× Enveric Biosciences Inc's market cap, and Allegion PLC pays a 1.55% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALLE | ENVB | |
|---|---|---|
Market Cap | $11.74B | $5.44M |
Sector | Industrials | Health |
52-Week High | $179.77 | $17.40 |
52-Week Low | $125.65 | $1.28 |
Enterprise Value | $13.46B | $529.67K |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
